New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
11:05 EDTAZN, CICigna, AstraZeneca in Crestor pact
Cigna (CI) has entered into a first-of-its-kind contract with AstraZeneca (AZN) to help ensure that customers are given an appropriate cholesterol-lowering medication based on their treatment needs. For Cigna customers who are at increased risk for atherosclerotic cardiovascular disease, ASCVD, and need to aggressively manage their low-density lipoprotein cholesterol, LDL-C, CRESTOR , a brand-name, cholesterol-lowering drug manufactured by AstraZeneca, can be prescribed and filled without requiring prior authorization. “Our arrangement with Cigna is an evolutionary step in supporting patient health, and facilitating access to CRESTOR for high risk patients. Predictive risk modeling can be used to help support the right treatment for the right patient at the right time, and we are excited to be working with Cigna because they are the only insurance carrier or Pharmacy Benefit Manager we have seen who has offered this capability,” says Philip de Vane, MD, Executive Director of US Medical Affairs, AstraZeneca.
News For AZN;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 21, 2014
07:15 EDTAZNFDA to hold workshop on breast cancer drug development
Subscribe for More Information
06:10 EDTAZNInovio, MedImmune, UPENN awarded $12.2M collaborative study by DARPA
Inovio Pharmaceuticals (INO) announced the Defense Advanced Research Projects Agency, or DARPA, has awarded $12.2M for a collaborative study that will be conducted by scientists from the Perelman School of Medicine at the University of Pennsylvania; Inovio Pharmaceuticals; and MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The group will develop DNA-based monoclonal antibodies, or mAbs, for infectious disease treatment. DARPA is an agency of the US Department of Defense that creates and supports novel technologies important for national security. Together, the three organizations will develop and assess the DNA mAbs in preclinical studies using technology developed by Penn and licensed by Inovio. The collaboration will focus on three disease areas – influenza virus, Pseudomonas aeruginosa and Staphylococcus aureus.
October 20, 2014
07:47 EDTAZNPfizer less likely to renew Astra pursuit after Shire deal breakdown, FT says
Subscribe for More Information
07:19 EDTAZNIBC Life Sciences to hold a conference
Subscribe for More Information
07:14 EDTAZNEuropean College of Neuropsychopharmacology to hold a conference
27th ECNP Congress is being held in Berlin, Germany on October 18-21.
October 15, 2014
10:48 EDTAZNShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
October 14, 2014
11:23 EDTAZNBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
10:01 EDTCIOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:40 EDTCICigna downgraded at Sterne Agee
Subscribe for More Information
05:49 EDTCICigna downgraded to Neutral from Buy at Sterne Agee
Subscribe for More Information
October 13, 2014
10:08 EDTAZNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:21 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
07:53 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
05:27 EDTAZNAstraZeneca upgraded to Buy from Hold at Jefferies
Subscribe for More Information
October 9, 2014
08:10 EDTAZNAstraZeneca reports Phase IIb study of benralizumab met primary endpoint
Subscribe for More Information
October 7, 2014
07:48 EDTAZNSalix reinstated with a Buy at Jefferies
Subscribe for More Information
07:12 EDTCICigna price target raised to $110 from $95 at JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use